TP53 and uterine carcinosarcoma: In the MSK-MET data set with POLD1 alterations, patients with EC had excellent outcomes regardless of race (5 Asian patients; 6 Black patients,; 58 White patients; P = .13), histology (72 patients with UEC and 3 with uterine serious carcinoma or uterine carcinosarcoma; P = .74), or TP53 altered status (24 with TP53 altered; 51 with TP53 wildtype; P = .10) (Figure 3).